🇺🇸 FDA
Pipeline program

DNL628

DNLI-K-0001

Phase 1 small_molecule active

Quick answer

DNL628 for Alzheimer Disease, Early Onset is a Phase 1 program (small_molecule) at Denali Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Denali Therapeutics
Indication
Alzheimer Disease, Early Onset
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials